PRAK-03202: A triple antigen virus-like particle vaccine candidate against SARS CoV-2

Article activity feed

1. Version published to 10.1016/j.heliyon.2021.e08124

   Oct 1, 2021
2. 

   ScreenIT

   Nov 2, 2020

   SciScore for 10.1101/2020.10.30.360115: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	IRB: The study is approved by the Institutional Ethics committee at Premas Biotech Pvt. Ltd. BrDU assay: PBMCs were separated from the blood of the convalescent patients and stimulated with two doses of PRAK-03202 (2.5μg and 5μg).
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Serum Antibody Measurements: IgG mediated antibody titer of serum samples collected from immunized animals and convalescent patients’ sera were determined by enzyme-linked immunosorbent assay (ELISA)35 using 1:5000 dilution of HRP conjugated …

   SciScore for 10.1101/2020.10.30.360115: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	IRB: The study is approved by the Institutional Ethics committee at Premas Biotech Pvt. Ltd. BrDU assay: PBMCs were separated from the blood of the convalescent patients and stimulated with two doses of PRAK-03202 (2.5μg and 5μg).
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Serum Antibody Measurements: IgG mediated antibody titer of serum samples collected from immunized animals and convalescent patients’ sera were determined by enzyme-linked immunosorbent assay (ELISA)35 using 1:5000 dilution of HRP conjugated anti mouse (A4416, Sigma-Aldrich, USA) and 1:10000 dilution of HRP conjugated anti human secondary antibody (A0170, Sigma-Aldrich, USA) respectively.	anti mouse ( A4416 suggested: None anti human secondary antibody ( A0170 suggested: None
   Diluted sera (1:1000) were applied to each well for 2h at 37°C, followed by incubation with HRP conjugated goat anti-mouse antibodies for 1h at 37°C after 3 times PBS wash.	anti-mouse suggested: None
   , B cells (Cat≠1115535; Biolegend), NK (Cat≠108905; Biolegend), Ly6B (Cat≠127629; Biolegend) antibodies.	Ly6B suggested: None
   Total IgG response was evaluated by enzyme-linked immunosorbent assays (ELISAs) using 1:5000 dilution of HRP conjugated anti mouse secondary antibody (A4416, Sigma-Aldrich, USA).	anti mouse suggested: None
   Experimental Models: Cell Lines
   Sentences	Resources
   Binding affinity of PRAK-03202: Flow cytometry analysis was performed to detect the binding of PRAK-03202 to hACE2 receptor in Hep-G2 cells and MCF-7 cells.	MCF-7 suggested: NCI-DTP Cat# MCF7, RRID:CVCL_0031)
   3 μg of purified PRAK-03202 was labelled with 5 μM of CFSE (Thermo, C34554) for 3 hrs at room temperature, which was followed by incubation with Hep-G2 and MCF-7 (5 x 104 cells/100 100 μl) cells for 1 hr on ice).	Hep-G2 suggested: None
   The virus-serum mixture was added to the pre-seeded Vero E6 cells and incubated at 37°C for 1 hour.	Vero E6 suggested: None
   Experimental Models: Organisms/Strains
   Sentences	Resources
   Mice: Specific pathogen-free 6-8 weeks-old BALB/c mice were maintained in the DHITI Life Sciences, India.	BALB/c suggested: RRID:IMSR_ORNL:BALB/cRl)
   Software and Algorithms
   Sentences	Resources
   After centrifugation and two times washing with FACS buffer, data were acquired using a BD FACS Canto II and analyzed using FlowJo (TreeStar).	FlowJo suggested: (FlowJo, RRID:SCR_008520)
   All the statistical analysis was performed using OriginPro (Version:2020b).	OriginPro suggested: None

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Read the original source
3. 

   Version published to 10.1101/2020.10.30.360115 on bioRxiv

   Oct 30, 2020